Imaging Technology

JUNE 10, 2024

More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug. Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

Nuclear Medicine 104

Nuclear Medicine Radiopharmaceuticals Disease Diagnostic 104

AuntMinnie

JUNE 9, 2024

Her research also contributed to FDA approval of Lu-177 DOTATATE for treating neuroendocrine tumors; recently, she and collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, which has been approved for human studies by the FDA as an Investigational New Drug (IND).

Nuclear Medicine 98

Nuclear Medicine Radiopharmaceuticals Disease Imaging 98

AuntMinnie

JANUARY 19, 2024

more than 6 million Americans have Alzheimer's disease, a debilitating and far-reaching disease that accounts for 60% to 80% of dementia cases, and by 2050, this number is projected to rise to nearly 13 million, according to Alzheimer’s Disease International. The disease affects memory, thinking, and behavior. In the U.S.,

Disease 52

Disease Medicare Imaging PET Scan 52

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

AuntMinnie

OCTOBER 25, 2024

His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Elliot Fishman, MD.

Nuclear Medicine 143

Nuclear Medicine Education Radiation Science Radiology Technologist 143